Get the latest on Ahern’s thoughts and company mentions
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium Lucius Partners Logo
The MHSRS is the Department of Defense’s largest scientific meeting and is designed to highlight new scientific approaches to address DoD research priorities. Military leaders, academic researchers, and industry present and collaborate on research / health care initiatives falling under numerous topic areas including Military Infectious Diseases.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
NEW YORK, July 14, 2022 /PRNewswire/ — Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers. This is a well-validated murine model of HPV related cancers.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor
NEW YORK, July 12, 2022 /PRNewswire/ — Voltron Therapeutics, Inc. today announced that life science veteran, Dr. Tony Hodges, has joined the Company as Senior Scientific Advisor.
Dr. Hodges brings a wealth of experience in Transplant Medicine, Infectious Disease and clinical trials to help guide further development, and eventual commercialization, of products leveraging its Self-Assembling Vaccine (SAV) platform.
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
Lucius Partners, LLC has reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model. This study, if successful, may support filing of an Investigational New Drug (IND) application with the US Food and Drug Administration.
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology Lucius Partners Logo
NEW YORK, June 23, 2022 /PRNewswire/ — Lucius Partners, LLC today reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model. This study, if successful, may support filing of an Investigational New Drug (IND) application with the US Food and Drug Administration.
James Ahern Leads Laidlaw Venture Partners to Secure PIPE Financing for Odyssey Laidlaw Company Logo
Pairing to Facilitate Odyssey Concussion Study and Enhance Shareholder Value
New York , June 8, 2022 /PRNewswire/ — Health-tech focused venture capital firm, Laidlaw Venture Partners is pleased to announce it has secured PIPE financing for Odyssey Group, one of the world’s leading providers of reinsurance.
Jimmy Ahern Serves as Vice Chair for 7th Year as Laidlaw Sponsors Big Brothers Big Sisters Golf Classic 2022 to Raise $1 Million
Boston , June 6, 2022 /PRNewswire/ — New York-based venture capital firm, Laidlaw Capital Markets was honored to sponsor the world’s largest mentorship network, Big Brothers Big Sisters of Eastern Massachusetts for its keystone fundraiser.
Algorithm Sciences, a Laidlaw Venture Partners Portfolio Company, Announces Key Management Appointments
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced key management appointments for its portfolio company, Algorithm Sciences, Inc.
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
Amesite Inc. Closes $5.5 Million Financing and Go-Public Transaction
Company Developing an AI Powered Online Platform for Colleges and Universities
Laidlaw Venture Partners Portfolio Company AerWave Medical, Inc. Closes $4 Million Series A Financing Round
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.
Open source resources are paving the way for discovery and innovation across countless disciplines. Scholars, scientists and software developers alike are realizing the benefits that this type of collaboration can have for their respective industries and the world as a whole, as they work toward making open source a standard practice. Numerous verticals have demonstrated how open source software allows developers to balance customization. The seamless integration creates better products and more satisfactory user experiences, yet the healthcare industry has proven to be more apprehensive. In order for healthtech companies to get the maximum benefits of the open source community, they’ll need to address these three concerns.
A Pandemic Legacy: Saving Lives
The devastating impact of the COVID-19 pandemic is continuing to be felt, both in terms of human cost and the destruction it has wrought on the economies of the world. However, there looks to be a silver lining to the COVID cloud in the shape of medical research.
Business incubators serve a function that is sometimes overlooked in the birth of a startup, but for a fledgling company they can be the difference between success and failure. They can be defined as organizations that support the development of start-up companies in their very earliest stages—effectively, they turn an idea into a functioning business, transforming an embryonic startup into a confident and independent company.
Networking can get a bad rap, with the word bringing back the horror of having to make small talk at awkward events. However, at its core, effective networking is simply a case of identifying and forming mutually beneficial relationships.
Some aspects of networking are specific to investors, whereas others are particularly relevant to entrepreneurs and business founders. However, the two groups share one thing in common: they need each other to thrive. They are (or should be) looking for that new relationship that kick-starts the business or opens the door to a fantastic new investment opportunity.
All indications are that we’re heading toward an historic year for VC investment in healthtech. Looking at the US alone, the healthcare sector as a whole counts for 20% of GDP — a massive $4 trillion. One of the fastest growing parts of this sector is digital healthcare. Some estimates put the global market at $350 billion in 2019, with predictions for rapid growth over the next five years.
In the past, celebrities usually grew their wealth and status by acquiring real estate, opening restaurant chains, or launching fashion lines, but today’s celebrity is more likely to purchase cryptocurrency or invest in a high tech startup.
There is no doubt that over the past two years, since the global Covid crisis began, the world has changed and may never be the same again.